



**Clinical
Research
Laboratories, Inc.**

Final Report

**Evaluation of Skin Barrier Effects of Single
Applications of Topical Cosmetic Products via
Transepidermal Water Loss Measurements**

CLIENT: React, Inc.
3765 Kettle Court East
Delafield, WI 53018


ATTENTION: Mr. Bruce Tavares


TEST MATERIALS:


1. ENVIROPURE 301, Batch #H2031	7. ENVIROPURE 307, Batch #7172
2. ENVIROPURE 302, Batch #52902	8. ENVIROPURE 308, Batch #7182
3. ENVIROPURE 303, Batch #E2034	9. ENVIROPURE 309, Batch #7192
4. ENVIROPURE 304, Batch #E2035	10. ENVIROPURE 310
5. ENVIROPURE 305, Batch #7152	11. White Petrolatum
6. ENVIROPURE 306, Batch #7162	12. Vaseline

CRL STUDY NUMBER: CRL110302

AUTHORIZED SIGNATURES:


Bruce E. Kanengiser, M.D.
President/Medical Director


Marc J. Shaffer
Vice President of Scientific Affairs


Michael J. Muscatiello, Ph.D.
Executive Vice President/C.O.O.

REPORT DATE: February 3, 2003



**Clinical
Research
Laboratories, Inc.**


**Good Clinical Practice
Quality Assurance Audit Statement**

Clinical Study Number: CRL110302

Start Date: October 29, 2002


Completion Date: December 11, 2002

The Investigator/Project Manager verifies that the clinical study listed above was conducted following applicable guidelines and regulations established by U.S. Regulatory Agencies and in conformance with Clinical Research Laboratories, Inc. Standard Operating Procedures.




Signature of Investigator/Project Manager

Study related documents, including source documents or raw data, and final report were audited by the Clinical Research Laboratories, Inc. Quality Assurance Department on the date(s) listed below.



Signature of QA Auditor

Audit Date(s):





Clinical Research Laboratories, Inc.

*Final Report
Sponsor: React, Inc.
Study Number: CRL110302
Protocol Number: 3.03eu
Page 3 of 60*

FINAL REPORT

Evaluation of Skin Barrier Effects of Single Applications of Topical Cosmetic Products via Transepidermal Water Loss Measurements

PURPOSE

The purpose of this study was to determine and compare the potential of 12 topically applied products to protect or preserve skin barrier function after a single application of each product through the measurement of transepidermal water loss (TEWL).

INVESTIGATIVE SITE

Clinical Research Laboratories, Inc.
371 Hoes Lane
Piscataway, New Jersey 08854

TEST MATERIALS

The following test materials were provided by React, Inc. and were received by Clinical Research Laboratories, Inc. on September 23, 2002:

<u>Test Material</u>	<u>CRL Identification Number</u>
ENVIROPURE 301, Batch #H2031	CRL110302-1
ENVIROPURE 302, Batch #52902	CRL110302-2
ENVIROPURE 303, Batch #E2034	CRL110302-3
ENVIROPURE 304, Batch #E2035	CRL110302-4
ENVIROPURE 305, Batch #7152	CRL110302-5
ENVIROPURE 306, Batch #7162	CRL110302-6
ENVIROPURE 307, Batch #7172	CRL110302-7
ENVIROPURE 308, Batch #7182	CRL110302-8
ENVIROPURE 309, Batch #7192	CRL110302-9
ENVIROPURE 310	CRL110302-10

The test materials were coded with the CRL identification numbers listed above.



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 4 of 60

TEST MATERIALS (Continued)

The following test materials were provided by Clinical Research Laboratories, Inc. and were coded with the CRL identification numbers listed below:

<u>Test Material</u>	<u>CRL Identification Number</u>
White Petrolatum	CRL110302-11
Vaseline	CRL110302-12

STUDY DATES

This study was initiated on October 29, 2002 and was completed on December 11, 2002.

RATIONALE

The Tewameter is an instrument that measures the water loss from the skin surface. In this manner, the integrity of the barrier function of the skin, determined by the function of the stratum corneum layer of skin, can be measured in response to treatment with a test material. The loss of water through the skin surface, TEWL (transepidermal water loss), is expressed in units representing the amount of water (grams) leaving a given area of skin (square meter) in a unit of time (hour), resulting in TEWL units of g/m²h.

PANEL SELECTION

Fifty-five male and female panelists, ranging in age from 18 to 55 years, were selected for the study. All panelists signed an Informed Consent in conformance with 21 CFR Part 50: "Protection of Human Subjects" and completed a Panelist Profile/Medical History Form provided by Clinical Research Laboratories, Inc. prior to the study (Subject Demographics - Appendix I).

Subjects who met the following Inclusion/Exclusion Criteria were impaneled for the study:

Inclusion Criteria

- Female subjects between the ages of 18 and 55 years of age, in general good health, as determined by a Panelist Profile/Medical History Form;
- Subjects free of any dermatological disorders that may affect test results;



Clinical Research Laboratories, Inc.

*al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 5 of 60*

PANEL SELECTION (Continued)

Inclusion Criteria (Continued)

- Subjects willing to sign an Informed Consent Contract in conformance with 21 CFR Part 50: "Protection of Human Subjects";
- Subjects exhibiting dependability and intelligence in following directions;
- Subjects who have completed a Panelist Profile/Medical History Form.

Exclusion Criteria

- Pregnant or lactating females;
- Subjects receiving treatment with sympathomimetics, anti-histamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within 1 week prior to initiation of the study;
- Subjects with known allergies to cosmetic and toiletry products, or soybean products and soy derivatives;
- Subjects exhibiting a history of acute or chronic dermatologic, medical, and/or physical conditions which would preclude application of the test material(s) and/or could influence the outcome of the study.

TEST METHOD

Prior to the study, each subject was interviewed to determine eligibility. The test areas on the back of each candidate subject were examined to ensure that the skin was free of marks, abrasions, hair or other skin conditions that could interfere with study procedures. All eligible subjects equilibrated to ambient laboratory temperature and humidity for 30 minutes prior to initiation of test procedures.

Plastic templates were made for each subject to mark the locations of test sites, for subsequent identification during measurement, and to position treatment locations to isolate treated skin areas. Two templates, 1 for each side of the back, were created for each subject. Each template outlined a grid of 4 rows and 4 columns, measuring approximately 4 centimeters by 4 centimeters. The template was also marked to indicate positioning in relation to the middle of the back and the vertebral column. Within the grid on each template, alternate spaces in the grid were designated as treatment sites, with 7 cells on the left template and 6 cells on the right template labeled with a site number, as indicated schematically in the following table:



Clinical Research Laboratories, Inc.

Final Report
Sponsor: React, Inc.
Study Number: CRL110302
Protocol Number: 3.03eu
Page 6 of 60

TEST METHOD (Continued)

Left side template				Right side template			
	1		2	3		4	
5		6			7		8
	9		10	11		12	
		13					

Each site number was assigned as a treatment location for one of the test materials or as an untreated control site. The treatment assignment for each subject was determined by a computer-generated randomization code (Treatment Randomization - Appendix II).

Subjects were required to expose the skin of the back, laying face down on an examination table. The templates were placed against the skin of each side of the back and were used to mark the back with a gentian violet surgical marker. The back skin was marked by placing the gentian violet marker at holes in the plastic template at particular grid points. The marked points served as references for the placement of the template at each evaluation interval to identify treatment sites. Each of the 13 defined sites were measured in triplicate repetitions with the Tewameter. Triplicate readings were recorded on score sheets.

After baseline Tewameter readings were recorded, test materials were applied to treatment sites in accordance with the randomization code. To each 4 cm² test site, with the exception of the site assigned as untreated, 20 mg of the appropriate test material was applied, such that treated sites received 5 milligrams of test material per square centimeter of skin (5mg/ cm²). The test materials were rubbed into the 2 cm by 2 cm area of skin at each site using the finger of a gloved hand, with a different finger used for each test material and gloves changed when necessary. The site assigned as a control was not treated.

Subjects were required to remain on the examination table with the skin of the back exposed. At 1 hour from the time of application, triplicate Tewameter readings were taken from each test site. Subjects were then permitted to leave the laboratory, but were required to report to Clinical Research Laboratories, Inc. at 30 minutes prior to the 6-hour post-application reading. Times of return were recorded for each subject on an instruction sheet. Upon returning to Clinical Research Laboratories, Inc., subjects acclimated to ambient laboratory conditions for 30 minutes, and the 6-hour post-treatment Tewameter readings were taken and recorded.



Clinical Research Laboratories, Inc.

*al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 7 of 60*

STUDY RELATED COMMENTS

- Due to mechanical malfunction, the Tewameter was used in the evaluation of transepidermal water loss instead of the Evaporimeter, which was the instrument specified by the protocol. Both instruments utilize the same measurement principles, assessing the water evaporation gradient in an open chamber probe, and demonstrate correlating data under conditions such as the test method used in this study (Barel and Clarys 1995).
- The statistical method described by the study protocol referenced a comparison of medians between treatments. The most appropriate analysis of the data collected is a comparison of means as described in the Statistical Methods section below.

STATISTICAL METHODS

Triplicate readings for each test site were averaged for each evaluation interval. Average readings at baseline were compared to those at 1 hour and at 6 hours post-treatment for each treatment using standard paired t-tests. Two-tailed p-values were used to determine statistical significance. Changes in average Tewameter readings at the post-treatment intervals, relative to baseline, were compared for each treatment to the control by paired analysis using General Linear Modeling. A multiple variable analysis of variance (ANOVA) was used to determine the significance of differences between average Tewameter readings for each treatment or control for each interval and for changes from baseline at 1 hour and 6 hours post-treatment. Comparisons for which calculated p-values were less than or equal to 0.05 were considered statistically significant at the 95% confidence level.

RESULTS

Forty-nine subjects completed the study. Six subjects (#32, #43, #44, #45, #46 and #47) were discontinued for reasons unrelated to the test materials. One of these subjects, #32, was discontinued prior to test material application due to an allergic reaction to the gentian violet surgical marker. The remaining subjects were discontinued due to instrument malfunction, which prevented the capture of measurements for these subjects.



Clinical Research Laboratories, Inc.

*al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 8 of 60*

RESULTS (Continued)

Table I lists the average of triplicate Tewameter readings for each treatment and the percentage change from baseline in average readings at post-treatment intervals for each subject. The mean and standard deviation values for the Tewameter reading averages and changes from baseline of all subjects in the study population are listed in Table II for each treatment. Table III lists the variables calculated for the statistical analysis comparing average Tewameter readings at 1 hour and at 6 hours post-treatment to baseline. Table IV summarizes paired comparisons of changes in Tewameter readings of each test material to changes measured for the untreated control sites at 1 hour and at 6 hours post-application. Table V includes statistical variables related to the analysis of variance of average Tewameter readings at each interval and changes in readings from baseline at post-treatment intervals for all treatments and the control.

At 1 hour after application of each ENVIROPURE 304, Batch #E2035 (CRL110302-4) and ENVIROPURE 305, Batch #7152 (CRL110302-5), Tewameter readings of treated sites each decreased by 5% relative to baseline ($p=7.38E-03$ and $p=3.25E-02$). Tewameter readings at 6 hours for sites treated with these test materials were not statistically different from baseline Tewameter readings.

There were no statistically significant changes in average transepidermal water loss values measured at baseline compared to those measured at 1 hour or at 6 hours after treatment with ENVIROPURE 301, Batch #H2031 (CRL110302-1), ENVIROPURE 302, Batch #52902 (CRL110302-2), ENVIROPURE 303, Batch #E2034 (CRL110302-3), ENVIROPURE 306, Batch #7162 (CRL110302-6), ENVIROPURE 307, Batch #7172 (CRL110302-7), ENVIROPURE 308, Batch #7182 (CRL110302-8), ENVIROPURE 309, Batch #7192 (CRL110302-9), ENVIROPURE 310 (CRL110302-10), White Petrolatum (CRL110302-11) or Vaseline (CRL110302-12). No significant changes in Tewameter readings were measured for the untreated control sites at 1 hour or at 6 hours relative to baseline.

Paired comparisons of changes in Tewameter readings at post-treatment intervals for each test material relative to the untreated control demonstrated no statistically significant differences. Multiple variable comparisons of average Tewameter readings at each interval and of changes from baseline at 1 hour and at 6 hours post-treatment demonstrated no statistically significant differences between treatments, including application of any of the test materials and no treatment at the control sites.



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
e 9 of 60

CONCLUSION

Under the conditions of this study, no significant differences in the efficacies of the submitted test materials to protect or preserve skin barrier function were determined. Skin sites treated with each of the test materials, ENVIROPURE 301, Batch #H2031, ENVIROPURE 302, Batch #52902, ENVIROPURE 303, Batch #E2034, ENVIROPURE 304, Batch #E2035, ENVIROPURE 305, Batch #7152, ENVIROPURE 306, Batch #7162, ENVIROPURE 307, Batch #7172, ENVIROPURE 308, Batch #7182, ENVIROPURE 309, Batch #7192, ENVIROPURE 310, and the untreated control sites demonstrated statistically equivalent skin barrier effects. Tewameter readings at each interval and changes in Tewameter readings from baseline at 1 hour and at 6 hours post-treatment were not statistically different when all treatments were compared by analysis of variance. Paired analyses of each test material treatment and the control, with respect to the changes in transepidermal water loss at 1 hour and at 6 hours, also did not demonstrate statistically significant differences. The test materials ENVIROPURE 304, Batch #E2035 and ENVIROPURE 305, Batch #7152 exhibited evidence of eliciting a protective effect, in that the Tewameter readings at 1 hour after application of each of these test materials were significantly less than the readings at baseline. However, these decreases in transepidermal water loss were not statistically significant relative to changes measured for the control sites at 1 hour post-treatment.

RETENTION

All of the original case report forms used in this study will be retained by Clinical Research Laboratories, Inc. for a period of at least 5 years or as otherwise required by law.

Upon completion of the study, unused test materials will be returned to the Sponsor or archived by Clinical Research Laboratories, Inc. for a period no less than 6 months.

REFERENCES

Barel and Clarys. *Skin Pharmacology*. 186-195. 1995.



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 10 of 60

Table I

Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 301, Batch #H2031 (CRL110302-1)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	3.9	3.7	2.6	-4%	-33%
2	2.4	4.5	4.2	84%	71%
3	1.8	3.7	6.5	108%	266%
4	4.5	3.2	5.4	-30%	19%
5	6.0	6.2	5.3	2%	-13%
6	3.2	1.8	2.1	-45%	-36%
7	8.8	9.7	8.7	10%	0%
8	5.4	3.6	4.0	-34%	-26%
9	6.8	8.4	8.3	24%	22%
10	10.3	9.4	12.6	-8%	22%
11	10.8	6.6	9.0	-39%	-17%
12	6.4	5.0	9.3	-21%	45%
13	7.0	7.6	8.4	10%	21%
14	6.1	8.0	7.0	31%	14%
15	6.8	5.2	1.5	-24%	-77%
16	4.0	2.0	0.9	-49%	-77%
17	7.7	4.3	4.3	-44%	-44%
18	6.2	26.8	9.0	332%	45%
19	14.3	12.6	14.9	-12%	4%
20	5.4	6.3	4.7	16%	-14%
21	11.3	10.6	8.4	-6%	-26%
22	5.9	5.9	4.0	-1%	-33%
23	13.1	11.6	13.3	-11%	2%
24	3.4	7.0	8.0	105%	134%
25	10.8	13.2	11.1	22%	3%
26	10.0	11.9	12.6	19%	26%
27	6.3	6.1	6.1	-4%	-3%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 11 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 301, Batch #H2031 (CRL110302-1)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	10.6	9.1	8.6	-15%	-19%
29	12.9	9.6	11.2	-26%	-14%
30	21.2	19.3	25.6	-9%	21%
31	12.2	14.5	16.4	19%	35%
33	29.3	27.8	31.9	-5%	9%
34	21.2	22.0	24.3	4%	14%
35	21.4	24.4	19.3	14%	-10%
36	19.0	12.5	18.4	-34%	-3%
37	12.1	11.2	8.1	-7%	-33%
38	14.0	15.8	12.3	13%	-12%
39	7.4	8.2	6.8	10%	-9%
40	7.4	7.3	4.0	-2%	-45%
41	7.2	10.6	5.2	47%	-29%
42	10.5	7.3	8.6	-31%	-18%
48	8.4	7.5	8.9	-11%	6%
49	14.9	11.4	8.5	-24%	-43%
50	9.7	8.6	5.9	-11%	-40%
51	5.3	4.4	6.0	-18%	13%
52	8.1	5.4	8.6	-34%	6%
53	7.4	5.6	7.0	-24%	-5%
54	17.1	9.4	16.3	-45%	-5%
55	8.7	6.3	8.0	-28%	-8%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 12 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 302, Batch #52902 (CRL110302-2)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	2.8	1.9	1.2	-33%	-57%
2	5.2	3.4	2.4	-35%	-54%
3	2.3	3.4	5.4	44%	130%
4	3.3	3.1	3.6	-7%	7%
5	7.4	6.2	8.4	-17%	13%
6	4.2	3.0	1.5	-28%	-63%
7	5.4	5.2	3.4	-3%	-37%
8	5.2	4.0	2.3	-24%	-55%
9	8.0	8.2	9.1	2%	14%
10	9.1	8.9	10.3	-2%	14%
11	9.7	8.8	7.6	-10%	-22%
12	7.2	6.3	8.1	-13%	13%
13	6.9	8.5	7.6	23%	9%
14	5.1	4.5	5.2	-12%	1%
15	6.3	5.1	1.4	-20%	-77%
16	4.7	3.9	1.6	-16%	-66%
17	3.3	4.1	1.8	23%	-47%
18	7.8	9.4	9.0	20%	15%
19	13.5	12.8	14.7	-5%	9%
20	5.5	7.1	5.0	28%	-9%
21	10.8	8.7	7.9	-19%	-27%
22	8.5	7.4	4.9	-13%	-43%
23	11.9	9.9	7.0	-17%	-41%
24	7.9	8.7	9.6	10%	22%
25	5.7	7.1	17.2	26%	204%
26	11.9	9.8	10.2	-18%	-15%
27	7.2	6.6	7.2	-8%	0%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 13 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 302, Batch #52902 (CRL110302-2)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	11.9	9.4	8.2	-21%	-32%
29	12.7	10.7	12.2	-16%	-4%
30	12.0	14.3	19.4	19%	62%
31	17.1	18.6	22.2	9%	30%
33	19.6	23.9	24.1	22%	23%
34	21.0	23.2	28.7	10%	37%
35	24.0	27.8	24.2	16%	1%
36	11.8	8.9	10.8	-24%	-8%
37	10.3	13.8	9.5	34%	-8%
38	24.0	17.4	15.1	-28%	-37%
39	5.0	7.7	4.4	55%	-11%
40	8.6	7.3	5.7	-15%	-34%
41	7.2	7.5	7.8	4%	8%
42	6.1	3.6	2.4	-41%	-60%
48	8.4	7.1	10.6	-16%	25%
49	13.6	9.7	10.9	-28%	-20%
50	10.0	9.6	8.9	-4%	-11%
51	6.0	4.7	6.0	-22%	1%
52	12.9	8.3	12.5	-35%	-3%
53	4.7	4.5	4.7	-4%	-1%
54	12.5	10.9	9.8	-13%	-22%
55	9.4	5.9	8.0	-37%	-15%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 14 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 303, Batch #E2034 (CRL110302-3)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	4.4	4.2	3.1	-3%	-30%
2	6.4	5.9	3.2	-8%	-50%
3	2.1	4.4	5.0	111%	138%
4	2.4	3.0	3.1	24%	28%
5	5.1	5.5	6.3	7%	24%
6	3.0	2.8	1.6	-7%	-45%
7	5.0	2.3	1.6	-53%	-68%
8	2.4	2.8	2.0	15%	-18%
9	7.7	7.6	8.8	0%	15%
10	9.9	11.1	10.5	12%	6%
11	5.7	7.0	8.9	23%	55%
12	8.6	9.6	11.1	12%	29%
13	10.8	11.2	12.8	4%	19%
14	7.7	9.6	7.7	24%	0%
15	7.8	2.7	2.0	-65%	-75%
16	6.5	5.4	2.0	-16%	-69%
17	4.5	2.4	1.9	-48%	-58%
18	6.3	8.6	9.6	37%	52%
19	14.7	13.6	13.5	-8%	-8%
20	7.4	7.2	7.0	-3%	-6%
21	10.4	7.2	7.2	-31%	-31%
22	5.5	6.2	4.5	14%	-18%
23	13.0	8.8	9.0	-32%	-30%
24	6.3	6.2	10.4	-1%	66%
25	8.4	8.9	12.4	6%	48%
26	11.3	13.3	9.9	18%	-12%
27	4.9	7.4	5.7	51%	16%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 15 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 303, Batch #E2034 (CRL110302-3)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	11.2	8.8	10.2	-21%	-9%
29	15.1	18.8	11.9	24%	-21%
30	10.7	15.2	17.9	43%	68%
31	11.9	14.0	17.0	17%	42%
33	21.0	20.9	27.3	-1%	30%
34	18.7	19.6	22.5	4%	20%
35	22.5	26.4	28.5	17%	26%
36	12.3	10.4	11.2	-15%	-9%
37	7.4	6.9	6.4	-6%	-14%
38	24.2	46.1	11.2	91%	-54%
39	10.0	9.4	6.4	-5%	-35%
40	8.0	6.9	5.0	-13%	-37%
41	9.0	8.2	7.3	-9%	-18%
42	6.7	5.3	2.9	-21%	-57%
48	8.1	8.0	10.1	-2%	25%
49	14.2	9.4	10.8	-34%	-24%
50	10.0	10.1	9.0	1%	-10%
51	5.9	4.5	5.8	-23%	-1%
52	10.5	7.6	10.7	-28%	2%
53	7.5	7.3	7.1	-3%	-5%
54	15.3	12.3	12.9	-19%	-16%
55	7.4	7.7	8.8	4%	18%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 16 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 304, Batch #E2035 (CRL110302-4)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	5.4	4.6	2.5	-16%	-53%
2	3.4	3.8	4.3	13%	29%
3	1.8	3.6	4.6	102%	162%
4	3.5	3.9	4.2	13%	22%
5	7.0	5.2	6.7	-25%	-4%
6	2.3	1.4	2.7	-40%	18%
7	12.1	6.9	6.6	-43%	-45%
8	5.4	5.5	3.9	2%	-28%
9	4.5	9.9	8.9	121%	100%
10	11.3	10.9	11.7	-3%	4%
11	7.7	7.0	7.7	-10%	0%
12	6.9	6.8	8.5	-1%	24%
13	10.8	11.4	13.2	6%	22%
14	6.0	5.8	6.2	-3%	4%
15	6.9	5.3	0.6	-23%	-91%
16	3.4	1.9	1.7	-45%	-50%
17	12.9	2.9	1.5	-78%	-89%
18	7.4	5.8	9.0	-22%	21%
19	14.7	10.8	17.7	-26%	20%
20	4.8	6.1	5.0	27%	4%
21	12.4	11.6	9.5	-6%	-24%
22	8.1	7.9	6.1	-3%	-25%
23	12.4	9.5	8.4	-24%	-32%
24	6.6	5.5	10.4	-17%	57%
25	3.2	6.7	7.0	109%	120%
26	12.6	12.1	10.8	-3%	-14%
27	7.2	8.1	5.9	13%	-17%
28	10.5	10.4	8.0	-1%	-24%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 17 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 304, Batch #E2035 (CRL110302-4)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
29	18.0	12.2	13.4	-33%	-26%
30	10.7	13.0	16.8	21%	56%
31	13.2	14.3	18.2	8%	38%
33	26.2	23.3	33.8	-11%	29%
34	20.6	20.0	24.7	-3%	20%
35	24.2	24.4	23.6	1%	-2%
36	17.3	13.2	14.4	-24%	-16%
37	11.7	13.6	7.0	16%	-40%
38	15.8	17.7	15.3	12%	-3%
39	11.9	8.6	9.3	-28%	-22%
40	8.0	7.4	3.8	-8%	-53%
41	7.8	9.6	7.3	23%	-6%
42	16.7	6.1	9.1	-64%	-46%
48	8.9	6.6	10.8	-26%	21%
49	18.4	13.6	13.9	-26%	-24%
50	12.0	9.6	9.1	-20%	-24%
51	7.0	4.4	5.8	-38%	-18%
52	10.5	7.5	10.9	-28%	3%
53	6.9	7.1	7.6	2%	9%
54	13.9	10.3	11.8	-26%	-15%
55	7.9	7.8	7.2	-1%	-8%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 18 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 305, Batch #7152 (CRL110302-5)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	6.8	3.6	4.7	-47%	-31%
2	4.5	2.6	2.7	-43%	-41%
3	2.1	4.3	5.7	100%	166%
4	4.3	4.1	4.6	-5%	6%
5	5.1	6.3	4.6	23%	-10%
6	3.1	3.3	2.1	8%	-33%
7	5.6	2.5	1.6	-56%	-71%
8	3.5	2.2	2.5	-37%	-29%
9	6.5	7.7	8.6	18%	33%
10	7.7	9.7	8.0	26%	4%
11	12.8	7.9	10.6	-38%	-17%
12	8.3	7.9	10.4	-4%	26%
13	6.0	6.6	7.9	9%	31%
14	8.1	8.3	8.3	2%	3%
15	7.7	7.4	4.0	-4%	-48%
16	4.7	2.7	1.4	-42%	-70%
17	4.4	3.9	2.2	-12%	-49%
18	6.0	7.1	8.3	17%	38%
19	14.8	13.1	14.0	-11%	-5%
20	5.2	8.4	5.9	62%	13%
21	9.0	7.4	7.9	-18%	-12%
22	10.0	7.1	7.0	-29%	-30%
23	8.5	7.0	7.4	-18%	-13%
24	7.8	8.4	10.4	8%	33%
25	7.2	9.9	15.6	37%	116%
26	15.7	14.7	15.7	-6%	0%
27	12.1	11.4	11.8	-6%	-2%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 19 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 305, Batch #7152 (CRL110302-5)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	13.2	9.1	9.1	-31%	-31%
29	21.0	9.6	15.5	-54%	-26%
30	13.1	13.4	22.0	3%	68%
31	14.0	14.8	18.1	5%	29%
33	19.4	21.0	26.4	8%	36%
34	22.9	23.3	27.0	2%	18%
35	24.7	25.5	24.5	3%	-1%
36	11.0	10.7	10.4	-2%	-5%
37	11.9	11.7	9.1	-2%	-23%
38	13.9	15.2	8.1	9%	-42%
39	4.3	6.4	5.4	48%	26%
40	10.4	8.0	8.5	-23%	-18%
41	10.4	8.9	6.9	-15%	-34%
42	8.7	5.8	5.8	-34%	-34%
48	8.5	7.3	10.4	-14%	23%
49	12.3	10.0	5.5	-19%	-55%
50	10.9	9.1	7.9	-16%	-28%
51	4.8	4.2	4.6	-13%	-3%
52	11.5	6.8	10.2	-41%	-12%
53	4.6	6.5	6.0	43%	31%
54	11.3	10.6	10.2	-6%	-9%
55	6.9	6.3	9.0	-9%	31%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
e 20 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 306, Batch #7162 (CRL110302-6)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	4.6	4.4	5.2	-4%	13%
2	5.7	5.0	4.5	-12%	-21%
3	3.4	6.1	8.8	79%	155%
4	4.4	4.3	4.9	-4%	11%
5	5.0	4.3	4.2	-15%	-16%
6	1.4	2.1	1.5	56%	10%
7	4.3	5.1	6.9	18%	59%
8	5.2	3.9	3.8	-25%	-28%
9	7.8	7.3	9.6	-7%	23%
10	7.7	8.5	10.0	10%	30%
11	7.0	5.0	5.4	-29%	-23%
12	8.9	9.0	12.3	1%	38%
13	9.0	11.0	10.4	22%	16%
14	6.4	6.8	7.4	5%	15%
15	10.4	7.6	5.3	-27%	-49%
16	4.7	4.4	1.5	-6%	-69%
17	5.3	1.9	2.8	-63%	-47%
18	6.8	19.5	7.9	187%	17%
19	14.7	14.8	12.7	1%	-14%
20	5.8	6.2	5.2	7%	-11%
21	11.8	12.5	12.8	6%	9%
22	4.9	6.6	4.4	33%	-11%
23	11.2	9.4	9.7	-16%	-13%
24	4.9	7.3	9.0	49%	82%
25	6.9	11.4	12.2	66%	78%
26	10.8	11.5	9.5	7%	-11%
27	7.8	7.6	7.5	-3%	-3%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 21 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 306, Batch #7162 (CRL110302-6)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	10.3	9.7	10.7	-6%	4%
29	21.7	15.3	13.9	-30%	-36%
30	14.5	16.8	19.2	16%	32%
31	11.4	15.1	16.9	33%	48%
33	21.7	23.1	26.8	7%	24%
34	18.7	20.0	23.3	7%	25%
35	21.9	24.6	20.1	12%	-8%
36	14.6	10.7	10.6	-27%	-28%
37	8.4	7.6	4.1	-9%	-51%
38	18.6	18.6	12.7	0%	-32%
39	8.4	8.8	7.1	4%	-15%
40	6.6	6.8	4.9	3%	-27%
41	11.6	11.0	14.6	-5%	26%
42	11.8	13.1	9.5	11%	-20%
48	11.3	7.8	11.7	-31%	3%
49	17.0	11.3	11.4	-33%	-33%
50	11.6	10.1	9.0	-13%	-22%
51	5.3	3.9	5.8	-27%	9%
52	8.3	6.6	11.2	-21%	34%
53	6.8	7.0	5.7	3%	-15%
54	14.0	10.3	12.2	-27%	-13%
55	8.6	7.8	8.6	-9%	0%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 22 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 307, Batch #7172 (CRL110302-7)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	4.0	3.1	1.3	-21%	-66%
2	4.4	2.8	2.7	-36%	-37%
3	4.6	7.5	8.2	64%	79%
4	4.7	4.2	4.4	-10%	-6%
5	4.8	4.2	4.8	-13%	0%
6	4.2	2.5	1.2	-41%	-71%
7	6.0	2.3	1.4	-61%	-77%
8	4.5	2.0	2.6	-56%	-41%
9	7.2	7.4	7.8	2%	7%
10	11.3	9.3	11.7	-18%	3%
11	7.3	6.3	6.9	-14%	-5%
12	6.7	7.1	8.6	7%	30%
13	8.9	12.3	9.0	38%	1%
14	7.2	8.8	6.5	22%	-10%
15	7.0	6.2	4.0	-12%	-43%
16	6.2	4.8	2.4	-22%	-61%
17	6.2	4.7	3.7	-23%	-40%
18	6.9	6.9	8.3	0%	20%
19	15.3	16.2	16.7	6%	10%
20	5.5	6.7	6.8	21%	24%
21	12.4	10.9	9.6	-13%	-23%
22	7.4	5.6	7.1	-24%	-4%
23	10.7	10.9	7.5	2%	-29%
24	5.0	6.2	8.4	24%	67%
25	7.3	7.9	13.6	8%	87%
26	15.8	14.9	13.7	-5%	-14%
27	8.2	8.2	5.5	0%	-33%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 23 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 307, Batch #7172 (CRL110302-7)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	7.4	7.9	7.9	8%	8%
29	17.2	13.4	15.2	-22%	-12%
30	13.4	15.1	20.6	13%	54%
31	15.0	16.1	19.4	7%	30%
33	20.3	25.9	26.6	28%	31%
34	20.4	21.0	22.3	3%	10%
35	22.7	24.2	24.3	7%	7%
36	19.7	12.2	12.8	-38%	-35%
37	9.7	9.8	6.6	0%	-32%
38	14.5	14.7	9.4	1%	-35%
39	10.3	10.9	12.8	5%	24%
40	9.3	8.1	5.9	-13%	-36%
41	6.7	9.6	5.6	44%	-16%
42	14.1	9.5	12.6	-33%	-11%
48	7.0	7.1	8.4	2%	21%
49	19.5	13.4	15.9	-31%	-18%
50	13.5	11.0	12.2	-18%	-10%
51	6.4	5.0	5.8	-23%	-9%
52	10.6	7.9	12.2	-25%	15%
53	6.9	6.6	8.5	-4%	23%
54	13.3	12.2	12.7	-8%	-5%
55	8.1	6.0	8.6	-25%	7%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 24 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 308, Batch #7182 (CRL110302-8)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	9.7	6.6	5.9	-31%	-39%
2	7.7	3.0	3.4	-61%	-56%
3	2.3	4.1	5.5	80%	141%
4	5.7	6.6	5.6	16%	-1%
5	5.2	7.8	7.9	51%	54%
6	2.8	1.8	1.1	-38%	-60%
7	3.8	1.8	0.7	-53%	-81%
8	2.5	2.7	1.4	8%	-43%
9	6.3	6.8	7.8	8%	24%
10	7.3	9.9	9.5	36%	31%
11	11.7	10.2	13.8	-13%	17%
12	7.4	7.3	9.2	-1%	24%
13	5.8	9.1	9.0	57%	57%
14	8.4	10.5	8.4	25%	0%
15	8.4	6.9	3.9	-18%	-54%
16	5.6	3.0	1.9	-47%	-65%
17	7.5	8.8	3.3	16%	-57%
18	10.3	12.0	13.6	16%	32%
19	12.9	11.8	12.7	-9%	-2%
20	5.1	6.6	5.5	29%	7%
21	11.2	7.6	8.7	-32%	-22%
22	7.0	6.7	5.4	-5%	-23%
23	10.2	9.0	7.5	-11%	-26%
24	6.1	7.1	10.9	17%	78%
25	10.4	9.2	12.6	-12%	21%
26	8.5	9.6	10.5	13%	23%
27	10.1	9.0	7.0	-11%	-31%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 25 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 308, Batch #7182 (CRL110302-8)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	11.7	9.3	10.0	-20%	-14%
29	14.4	14.0	15.1	-3%	5%
30	16.9	19.1	25.5	13%	51%
31	14.9	23.3	22.9	56%	54%
33	19.2	19.7	24.1	2%	25%
34	19.8	21.8	24.5	10%	23%
35	21.0	24.0	22.2	14%	6%
36	14.3	11.0	9.2	-23%	-36%
37	9.0	15.4	10.0	71%	11%
38	23.4	48.8	12.5	108%	-47%
39	7.4	7.0	6.3	-5%	-14%
40	8.6	8.0	7.6	-8%	-12%
41	8.5	8.6	7.2	1%	-15%
42	9.4	5.4	0.0	-42%	-100%
48	6.6	7.4	7.3	11%	10%
49	16.0	10.6	12.3	-34%	-23%
50	10.5	9.5	8.8	-9%	-16%
51	5.9	4.6	5.6	-21%	-5%
52	14.1	9.1	12.1	-36%	-15%
53	5.9	5.4	5.8	-8%	-2%
54	10.7	9.0	10.5	-15%	-1%
55	6.7	5.9	9.8	-12%	46%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 26 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 309, Batch #7192 (CRL110302-9)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	3.0	4.4	1.6	47%	-46%
2	5.3	3.3	4.2	-38%	-20%
3	3.8	4.6	6.2	22%	64%
4	2.6	3.4	4.1	32%	60%
5	8.7	8.4	7.8	-4%	-11%
6	6.6	2.9	4.7	-56%	-29%
7	5.5	2.5	3.7	-54%	-33%
8	5.1	6.9	3.3	35%	-36%
9	6.9	7.8	10.5	13%	51%
10	8.5	9.3	7.6	9%	-11%
11	5.8	5.8	6.4	0%	10%
12	11.8	9.8	13.8	-17%	16%
13	11.2	8.8	11.8	-21%	5%
14	5.3	5.2	6.1	-2%	16%
15	9.0	6.1	4.2	-33%	-53%
16	4.5	3.4	1.9	-23%	-57%
17	8.0	4.2	2.9	-48%	-63%
18	7.3	33.7	10.4	362%	43%
19	13.2	12.9	14.2	-3%	8%
20	5.4	6.8	6.4	26%	18%
21	14.8	13.3	9.6	-10%	-35%
22	6.6	5.2	5.9	-21%	-11%
23	8.8	8.6	5.2	-2%	-41%
24	5.4	5.9	7.8	9%	44%
25	6.1	13.5	11.4	121%	87%
26	9.4	11.2	10.0	19%	6%
27	7.0	7.7	3.7	11%	-47%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 27 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 309, Batch #7192 (CRL110302-9)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	13.1	10.5	9.2	-20%	-30%
29	21.3	12.0	14.1	-44%	-34%
30	14.3	15.4	21.3	8%	49%
31	15.9	17.1	19.1	8%	20%
33	23.1	24.1	27.5	4%	19%
34	19.4	21.2	27.2	9%	40%
35	21.2	23.7	20.6	12%	-3%
36	11.0	9.9	9.8	-11%	-11%
37	9.5	6.8	3.8	-28%	-60%
38	18.8	21.2	17.8	13%	-5%
39	8.6	10.0	8.3	17%	-4%
40	10.0	6.2	4.6	-38%	-54%
41	10.6	11.8	5.6	11%	-47%
42	12.7	8.1	6.2	-36%	-51%
48	12.1	7.0	10.7	-43%	-12%
49	14.1	10.4	9.2	-26%	-35%
50	11.5	10.7	8.7	-7%	-24%
51	5.4	4.3	6.1	-21%	13%
52	11.5	7.5	11.4	-35%	-1%
53	5.3	4.6	5.4	-13%	2%
54	15.1	12.4	13.5	-18%	-11%
55	10.1	7.2	7.2	-29%	-28%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 28 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	ENVIROPURE 310 (CRL110302-10)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	3.8	3.7	2.6	-3%	-32%
2	4.6	3.5	5.8	-24%	26%
3	4.0	9.6	9.0	139%	123%
4	4.6	5.7	4.8	24%	3%
5	5.5	6.3	6.4	14%	15%
6	4.8	3.9	3.5	-19%	-28%
7	9.7	6.4	8.5	-34%	-12%
8	3.9	4.3	2.2	9%	-44%
9	6.5	7.2	8.8	11%	36%
10	5.6	7.4	7.8	32%	40%
11	9.4	6.7	7.8	-29%	-17%
12	5.9	7.1	8.7	22%	49%
13	7.6	7.9	9.1	4%	19%
14	6.5	6.5	5.8	-1%	-12%
15	6.4	6.3	1.3	-2%	-80%
16	5.3	4.2	2.4	-20%	-54%
17	5.8	5.6	2.3	-3%	-61%
18	5.7	5.7	5.8	1%	2%
19	14.4	17.2	19.5	19%	35%
20	6.0	6.8	6.4	13%	7%
21	9.8	8.2	7.1	-16%	-27%
22	7.4	5.5	6.1	-25%	-18%
23	7.4	5.9	5.9	-21%	-21%
24	3.7	5.5	7.1	49%	95%
25	5.2	2.0	9.6	-61%	83%
26	15.7	13.3	14.8	-15%	-6%
27	7.6	7.9	5.5	3%	-28%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 29 of 60

**Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for
Each Subject**

Subject Number	ENVIROPURE 310 (CRL110302-10)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	10.4	9.4	6.1	-9%	-41%
29	25.2	19.2	18.8	-24%	-25%
30	15.5	18.2	16.7	18%	8%
31	14.1	15.5	19.7	10%	39%
33	25.0	28.5	26.9	14%	8%
34	21.8	21.2	27.6	-3%	26%
35	23.0	23.0	22.7	0%	-1%
36	10.2	8.4	7.3	-17%	-29%
37	8.3	7.3	4.1	-12%	-51%
38	13.6	18.2	9.7	34%	-28%
39	10.3	8.8	6.6	-15%	-36%
40	8.1	6.8	5.5	-16%	-32%
41	6.3	7.8	3.6	24%	-42%
42	14.3	13.5	12.6	-6%	-12%
48	8.0	6.5	9.0	-18%	12%
49	14.6	9.9	9.7	-33%	-34%
50	8.6	8.5	7.6	-1%	-12%
51	5.6	4.8	5.7	-14%	2%
52	10.1	6.9	10.4	-32%	3%
53	7.7	7.9	7.2	3%	-6%
54	12.8	10.9	12.2	-15%	-5%
55	8.5	5.9	7.5	-31%	-12%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 30 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	White Petrolatum (CRL110302-11)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	6.2	3.4	3.3	-45%	-48%
2	7.2	1.5	2.6	-80%	-64%
3	2.6	3.5	5.2	34%	97%
4	4.7	5.3	5.0	14%	6%
5	4.9	7.3	6.9	49%	41%
6	2.2	1.1	0.9	-48%	-59%
7	9.2	7.2	6.3	-22%	-31%
8	5.4	3.9	2.1	-28%	-60%
9	5.9	6.8	9.1	14%	54%
10	3.8	7.4	9.3	92%	142%
11	8.2	7.2	7.1	-11%	-13%
12	4.7	7.5	7.1	59%	49%
13	9.0	10.1	10.6	13%	19%
14	7.4	8.2	8.3	10%	11%
15	10.2	5.0	1.9	-51%	-81%
16	4.8	9.2	1.1	94%	-77%
17	7.2	5.1	4.9	-29%	-32%
18	8.8	9.4	8.6	6%	-2%
19	11.1	11.4	12.1	3%	9%
20	8.4	8.2	9.2	-2%	10%
21	18.5	12.7	14.7	-31%	-20%
22	5.9	7.4	8.7	26%	47%
23	12.2	6.6	7.5	-46%	-39%
24	5.5	7.5	9.2	37%	69%
25	2.7	7.5	11.6	180%	336%
26	7.4	10.6	10.5	43%	42%
27	8.9	6.7	8.8	-24%	-1%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 31 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	White Petrolatum (CRL110302-11)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	11.3	13.1	9.2	16%	-18%
29	13.1	12.6	11.9	-4%	-9%
30	17.1	20.7	29.2	21%	70%
31	13.4	15.3	16.4	14%	23%
33	24.4	25.9	30.0	6%	23%
34	21.1	21.4	25.3	1%	20%
35	21.4	25.5	21.0	19%	-2%
36	15.5	21.1	8.2	36%	-47%
37	7.4	4.6	4.1	-37%	-44%
38	14.7	16.4	10.0	11%	-32%
39	8.3	6.0	4.1	-28%	-50%
40	9.3	7.7	4.3	-17%	-53%
41	8.2	16.7	10.3	102%	25%
42	11.3	5.8	4.0	-48%	-65%
48	14.0	6.6	12.3	-53%	-12%
49	19.7	10.6	12.8	-46%	-35%
50	9.4	9.7	8.7	4%	-7%
51	6.4	7.1	6.3	10%	-2%
52	10.8	8.5	11.0	-22%	2%
53	5.2	4.4	4.7	-15%	-10%
54	12.2	11.1	14.0	-9%	14%
55	8.9	4.2	7.5	-53%	-16%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 32 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	Vaseline (CRL110302-12)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	5.0	5.0	3.2	-1%	-37%
2	6.8	4.0	4.2	-41%	-38%
3	3.0	4.7	5.1	57%	71%
4	2.1	4.0	3.8	89%	81%
5	5.7	7.1	6.9	26%	21%
6	4.2	3.6	1.5	-15%	-65%
7	5.3	5.0	4.5	-5%	-15%
8	8.1	4.9	5.8	-40%	-29%
9	9.1	9.7	10.8	7%	19%
10	9.6	8.2	9.5	-15%	-1%
11	5.9	5.7	7.0	-3%	19%
12	7.2	8.2	9.1	13%	26%
13	6.9	8.3	9.6	20%	39%
14	4.5	7.0	6.2	57%	39%
15	9.0	6.6	4.5	-27%	-51%
16	6.0	7.4	1.1	23%	-82%
17	4.2	2.9	1.9	-32%	-55%
18	7.8	7.6	10.0	-3%	28%
19	14.7	11.1	14.9	-24%	1%
20	5.7	6.8	6.2	20%	9%
21	15.1	9.7	11.2	-36%	-26%
22	7.0	7.0	5.6	0%	-21%
23	8.6	5.3	6.8	-38%	-21%
24	4.5	4.8	7.6	7%	69%
25	5.7	8.0	9.1	41%	59%
26	12.1	11.7	12.1	-3%	0%
27	8.0	13.4	4.5	67%	-44%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 33 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	Vaseline (CRL110302-12)				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	11.3	10.4	8.6	-8%	-24%
29	20.8	12.2	13.4	-41%	-36%
30	12.2	14.3	17.0	18%	39%
31	18.3	16.8	25.2	-9%	37%
33	19.5	22.6	26.1	16%	34%
34	23.6	22.9	30.1	-3%	28%
35	26.5	24.8	25.0	-6%	-6%
36	11.7	11.6	6.3	-1%	-46%
37	8.3	5.9	4.9	-28%	-41%
38	13.6	15.5	9.8	14%	-28%
39	5.2	6.7	4.6	30%	-12%
40	6.9	6.5	3.4	-6%	-50%
41	12.1	15.8	16.6	30%	37%
42	18.8	7.9	9.1	-58%	-52%
48	8.5	6.9	9.6	-18%	13%
49	15.4	12.0	12.5	-22%	-19%
50	11.7	10.5	10.3	-10%	-12%
51	5.4	5.0	5.9	-7%	8%
52	11.7	8.8	11.9	-25%	2%
53	7.4	6.7	9.4	-9%	27%
54	12.5	9.8	9.8	-22%	-22%
55	9.2	6.4	7.4	-30%	-20%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 34 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	Untreated Control				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
1	3.0	4.1	2.0	37%	-33%
2	5.1	3.9	3.2	-24%	-38%
3	7.5	6.9	9.3	-8%	24%
4	5.1	5.4	6.8	7%	33%
5	6.0	4.4	5.1	-27%	-15%
6	6.3	3.8	2.5	-40%	-60%
7	8.2	5.8	4.7	-29%	-42%
8	3.6	1.6	5.7	-55%	56%
9	9.4	9.7	12.2	2%	29%
10	8.6	10.0	11.1	17%	30%
11	8.0	6.5	7.7	-19%	-4%
12	6.6	6.4	8.0	-4%	21%
13	5.9	7.9	8.4	34%	43%
14	5.0	5.3	6.5	7%	32%
15	7.3	4.1	2.8	-44%	-62%
16	3.5	1.1	2.1	-67%	-40%
17	5.0	6.3	1.6	27%	-67%
18	6.3	8.7	9.4	38%	49%
19	13.2	15.3	14.4	16%	9%
20	7.9	8.4	6.4	7%	-19%
21	10.9	10.9	8.8	0%	-19%
22	9.4	8.7	9.0	-8%	-5%
23	13.8	12.3	8.4	-11%	-39%
24	4.1	4.4	7.9	6%	90%
25	16.1	7.4	9.7	-54%	-39%
26	11.1	10.0	9.6	-10%	-14%
27	6.7	6.5	4.3	-3%	-36%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 35 of 60

Table I
(Continued)
Tewameter Readings at Each Interval and Percentage Change Values from Baseline for Each Subject

Subject Number	Untreated Control				
	Baseline	1 Hour	6 Hours	1 Hour	6 Hours
28	9.5	7.9	9.2	-17%	-3%
29	18.7	20.5	14.8	9%	-21%
30	14.2	15.8	22.8	11%	60%
31	12.9	15.8	18.4	22%	43%
33	26.2	27.5	30.5	5%	17%
34	19.1	19.3	24.4	1%	28%
35	26.5	25.2	27.0	-5%	2%
36	19.0	18.1	19.0	-5%	0%
37	8.9	9.3	6.5	4%	-27%
38	20.4	26.0	11.6	27%	-43%
39	7.6	7.6	6.6	0%	-13%
40	6.5	6.1	3.9	-6%	-41%
41	7.3	7.0	5.7	-5%	-22%
42	19.2	13.7	2.0	-29%	-89%
48	7.1	6.5	7.3	-8%	3%
49	17.2	16.7	13.5	-3%	-22%
50	12.8	12.1	11.4	-5%	-11%
51	5.1	4.3	5.7	-16%	12%
52	9.2	6.4	10.6	-30%	15%
53	9.2	8.2	14.6	-11%	59%
54	10.2	10.5	10.2	2%	-1%
55	8.1	6.7	8.1	-17%	0%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 36 of 60

Table II

Population Mean and Standard Deviation Values for Tewameter Readings and Percentage Changes from Baseline

Treatment	Statistic	TEWL Values			% Change from Baseline	
		Baseline	1 Hour	6 Hours	1 Hour	6 Hours
ENVIROPURE 301, Batch #H2031 (CRL110302-1)	Mean	9.7	9.5	9.4	4%	2%
	St. dev.	5.6	6.0	6.2	59%	52%
ENVIROPURE 302, Batch #52902 (CRL110302-2)	Mean	9.3	8.8	9.0	-5%	-5%
	St. dev.	5.1	5.5	6.3	22%	47%
ENVIROPURE 303, Batch #E2034 (CRL110302-3)	Mean	9.3	9.6	9.0	2%	-2%
	St. dev.	5.0	7.3	5.9	31%	41%
ENVIROPURE 304, Batch #E2035 (CRL110302-4)	Mean	10.2	9.0	9.5	-5%	0%
	St. dev.	5.5	5.0	6.3	37%	46%
ENVIROPURE 305, Batch #7152 (CRL110302-5)	Mean	9.5	8.8	9.3	-5%	-1%
	St. dev.	5.1	5.0	6.1	30%	43%
ENVIROPURE 306, Batch #7162 (CRL110302-6)	Mean	9.6	9.6	9.5	4%	3%
	St. dev.	5.0	5.2	5.3	37%	39%
ENVIROPURE 307, Batch #7172 (CRL110302-7)	Mean	9.9	9.3	9.6	-6%	-5%
	St. dev.	5.0	5.3	5.9	24%	35%
ENVIROPURE 308, Batch #7182 (CRL110302-8)	Mean	9.7	10.0	9.4	2%	-2%
	St. dev.	4.8	7.6	6.1	34%	43%
ENVIROPURE 309, Batch #7192 (CRL110302-9)	Mean	10.0	9.7	9.2	2%	-7%
	St. dev.	5.0	6.3	6.0	61%	36%
ENVIROPURE 310 (CRL110302-10)	Mean	9.5	9.1	9.0	-2%	-4%
	St. dev.	5.4	5.6	6.1	29%	39%
White Petrolatum (CRL110302-11)	Mean	9.7	9.4	9.3	3%	4%
	St. dev.	5.2	5.7	6.3	47%	67%
Vaseline (CRL110302-12)	Mean	9.8	9.1	9.4	-1%	-3%
	St. dev.	5.4	5.0	6.4	30%	38%
Untreated Control	Mean	10.2	9.7	9.6	-6%	-3%
	St. dev.	5.7	6.2	6.5	23%	37%



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 37 of 60

Table III

Summary Statistics for the Determination of Statistical Significance Between Baseline and Post-Treatment Tewameter Readings

Treatment: ENVIROPURE 301, Batch #H2031 (CRL110302-1)

	Transepidermal Water Loss (g/hm ²)	
	Baseline	1 Hour
Mean	9.7	9.5
Variance	31.5	35.9
Observations	49	49
Pearson Correlation	0.78	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.43	
P(T<=t) one-tail	0.34	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.67	
t Critical two-tail	2.01	

	Baseline	6 Hours
	Mean	9.7
Variance	31.5	38.9
Observations	49	49
Pearson Correlation	0.91	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.70	
P(T<=t) one-tail	0.24	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.49	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 38 of 60

**Table III
(Continued)**
**Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings**

Treatment: ENVIROPURE 302, Batch
#52902 (CRL110302-2)

	Transepidermal Water Loss (g/hm²)	
	Baseline	1 Hour
Mean	9.3	8.8
Variance	26.0	30.0
Observations	49	49
Pearson Correlation	0.92	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.67	
P(T<=t) one-tail	0.05	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.10	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.3	9.0
Variance	26.0	39.9
Observations	49	49
Pearson Correlation	0.84	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.66	
P(T<=t) one-tail	0.26	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.51	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 39 of 60

**Table III
(Continued)**
**Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings**

Treatment: ENVIROPURE 303, Batch
#E2034 (CRL110302-3)

	Transepidermal Water Loss (g/hm²)	
	Baseline	1 Hour
Mean	9.3	9.6
Variance	24.7	53.0
Observations	49	49
Pearson Correlation	0.88	
Hypothesized Mean Difference	0	
df	48	
t Stat	-0.49	
P(T<=t) one-tail	0.31	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.63	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.3	9.0
Variance	24.7	35.3
Observations	49	49
Pearson Correlation	0.80	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.57	
P(T<=t) one-tail	0.29	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.57	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 40 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline and Post-Treatment Tewameter Readings

Treatment: ENVIROPURE 304, Batch #E2035 (CRL110302-4)

	Transepidermal Water Loss (g/hm²)	
Mean	10.2	9.0
Variance	30.2	24.6
Observations	49	49
Pearson Correlation	0.85	
Hypothesized Mean Difference	0	
df	48	
t Stat	2.80	
P(T<=t) one-tail	3.69E-03	
t Critical one-tail	1.68	
P(T<=t) two-tail	7.38E-03	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	10.2	9.5
Variance	30.2	39.6
Observations	49	49
Pearson Correlation	0.82	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.26	
P(T<=t) one-tail	0.11	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.21	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 41 of 60

**Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings**

Treatment: ENVIROPURE 305, Batch
#7152 (CRL110302-5)

	Transepidermal Water Loss (g/hm²)	
	Baseline	1 Hour
Mean	9.5	8.8
Variance	26.0	24.6
Observations	49	49
Pearson Correlation	0.88	
Hypothesized Mean Difference	0	
df	48	
t Stat	2.20	
P(T<=t) one-tail	1.63E-02	
t Critical one-tail	1.68	
P(T<=t) two-tail	3.25E-02	
t Critical two-tail	2.01	

	Baseline	6 Hours
	Mean	9.5
Variance	26.0	36.8
Observations	49	49
Pearson Correlation	0.84	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.55	
P(T<=t) one-tail	0.29	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.58	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 42 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings

Treatment: ENVIROPURE 306, Batch
 #7162 (CRL110302-6)

Transepidermal Water Loss (g/hm²)		
	Baseline	1 Hour
Mean	9.6	9.6
Variance	25.3	27.5
Observations	49	49
Pearson Correlation	0.85	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.02	
P(T<=t) one-tail	0.49	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.98	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.6	9.5
Variance	25.3	28.0
Observations	49	49
Pearson Correlation	0.82	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.21	
P(T<=t) one-tail	0.42	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.84	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 43 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings

Treatment: ENVIROPURE 307, Batch
 #7172 (CRL110302-7)

Transepidermal Water Loss (g/hm²)		
	Baseline	1 Hour
Mean	9.9	9.3
Variance	25.2	27.7
Observations	49	49
Pearson Correlation	0.90	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.76	
P(T<=t) one-tail	0.04	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.09	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.9	9.6
Variance	25.2	35.2
Observations	49	49
Pearson Correlation	0.87	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.72	
P(T<=t) one-tail	0.24	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.47	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 44 of 60

**Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings**

Treatment: ENVIROPURE 308, Batch
#7182 (CRL110302-8)

	Transepidermal Water Loss (g/hm²)	
	Baseline	1 Hour
Mean	9.7	10.0
Variance	23.0	57.9
Observations	49	49
Pearson Correlation	0.83	
Hypothesized Mean Difference	0	
df	48	
t Stat	-0.56	
P(T<=t) one-tail	0.29	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.58	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.7	9.4
Variance	23.0	36.8
Observations	49	49
Pearson Correlation	0.79	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.49	
P(T<=t) one-tail	0.31	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.63	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 45 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings

Treatment: ENVIROPURE 309, Batch
 #7192 (CRL110302-9)

Transepidermal Water Loss (g/hm²)		
	Baseline	1 Hour
Mean	10.0	9.7
Variance	24.9	39.6
Observations	49	49
Pearson Correlation	0.68	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.38	
P(T<=t) one-tail	0.35	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.71	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	10.0	9.2
Variance	24.9	36.0
Observations	49	49
Pearson Correlation	0.83	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.58	
P(T<=t) one-tail	0.06	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.12	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 46 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings

Treatment: ENVIROPURE 310
 (CRL110302-10)

	Transepidermal Water Loss (g/hm²)	
	Baseline	1 Hour
Mean	9.5	9.1
Variance	29.5	31.2
Observations	49	49
Pearson Correlation	0.92	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.14	
P(T<=t) one-tail	0.13	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.26	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.5	9.0
Variance	29.5	36.7
Observations	49	49
Pearson Correlation	0.88	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.14	
P(T<=t) one-tail	0.13	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.26	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 47 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings

Treatment: White Petrolatum
 (CRL110302-11)

	Transepidermal Water Loss (g/hm²)	
	Baseline	1 Hour
Mean	9.7	9.4
Variance	26.5	33.0
Observations	49	49
Pearson Correlation	0.80	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.54	
P(T<=t) one-tail	0.29	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.59	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.7	9.3
Variance	26.5	40.0
Observations	49	49
Pearson Correlation	0.77	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.64	
P(T<=t) one-tail	0.26	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.53	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 48 of 60

**Table III
(Continued)**
**Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings**

Treatment: Vaseline (CRL110302-12)		
Transepidermal Water Loss (g/hm²)		
	Baseline	1 Hour
Mean	9.8	9.1
Variance	29.7	24.5
Observations	49	49
Pearson Correlation	0.85	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.74	
P(T<=t) one-tail	0.04	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.09	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	9.8	9.4
Variance	29.7	40.4
Observations	49	49
Pearson Correlation	0.84	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.94	
P(T<=t) one-tail	0.18	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.35	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
ge 49 of 60

Table III
(Continued)
Summary Statistics for the Determination of Statistical Significance Between Baseline
and Post-Treatment Tewameter Readings

Treatment: Untreated Control		
Transepidermal Water Loss (g/hm²)		
	Baseline	1 Hour
Mean	10.2	9.7
Variance	32.4	37.9
Observations	49	49
Pearson Correlation	0.94	
Hypothesized Mean Difference	0	
df	48	
t Stat	1.42	
P(T<=t) one-tail	0.08	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.16	
t Critical two-tail	2.01	

	Baseline	6 Hours
Mean	10.2	9.6
Variance	32.4	41.6
Observations	49	49
Pearson Correlation	0.78	
Hypothesized Mean Difference	0	
df	48	
t Stat	0.95	
P(T<=t) one-tail	0.17	
t Critical one-tail	1.68	
P(T<=t) two-tail	0.35	
t Critical two-tail	2.01	



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 50 of 60

Table IV

Summary Statistics for the Determination of Statistically Significant Differences Between Each Treatment and the Control

Paired Analysis of Treatments and the Control for Changes in Tewameter Readings from Baseline at 1 Hour Post-Treatment					
Comparison	DF	Contrast SS	Mean Square	F Value	Pr > F
A vs. M	1	0.04920304	0.04920304	0.41	0.5218
B vs. M	1	0.01298792	0.01298792	0.11	0.7420
C vs. M	1	0.03903883	0.03903883	0.33	0.5683
D vs. M	1	0.04546382	0.04546382	0.38	0.5381
E vs. M	1	0.02192521	0.02192521	0.18	0.6689
F vs. M	1	0.05461275	0.05461275	0.46	0.4998
G vs. M	1	0.03257827	0.03257827	0.27	0.6022
H vs. M	1	0.05408176	0.05408176	0.45	0.5019
I vs. M	1	0.02727884	0.02727884	0.23	0.6334
J vs. M	1	0.00049521	0.00049521	0.00	0.9488
K vs. M	1	0.02079177	0.02079177	0.17	0.6771
L vs. M	1	0.00474670	0.00474670	0.04	0.8423

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 51 of 60

**Table IV
(Continued)
Summary Statistics for the Determination of Statistically Significant Differences
Between Each Treatment and the Control**

Paired Analysis of Treatments and the Control for Changes in Tewameter Readings from Baseline at 6 Hours Post-Treatment					
Comparison	DF	Contrast SS	Mean Square	F Value	Pr > F
A vs. M	1	0.00198419	0.00198419	0.02	0.8934
B vs. M	1	0.13233768	0.13233768	1.20	0.2740
C vs. M	1	0.01263662	0.01263662	0.11	0.7352
D vs. M	1	0.01520318	0.01520318	0.14	0.7107
E vs. M	1	0.01699027	0.01699027	0.15	0.6950
F vs. M	1	0.00616431	0.00616431	0.06	0.8133
G vs. M	1	0.05272068	0.05272068	0.48	0.4898
H vs. M	1	0.01569261	0.01569261	0.14	0.7063
I vs. M	1	0.08728030	0.08728030	0.79	0.3743
J vs. M	1	0.05606925	0.05606925	0.51	0.4763
K vs. M	1	0.00613344	0.00613344	0.06	0.8137
L vs. M	1	0.00969366	0.00969366	0.09	0.7671

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 52 of 60

Table V

Summary Statistics for Multiple Treatment Comparisons for Between Treatments and the Control

Baseline

Alpha	0.05
Error Degrees of Freedom	585
Error Mean Square	27.19606
Critical Value of Studentized Range	4.70451
Minimum Significant Difference	3.6173

Tukey Grouping*	Mean	N	Product
A	9.970	46	A
A	9.913	46	H
A	9.885	46	F
A	9.824	46	J
A	9.785	46	E
A	9.559	46	B
A	9.543	46	C
A	10.591	46	D
A	10.324	46	I
A	10.235	46	M
A	10.200	46	L
A	10.191	46	G
A	10.115	46	K

***Means with the same letter are not significantly different.**

Treatment Code

A	=	ENVIOPURE 301, Batch #H2031 (CRL110302-1)
B	=	ENVIOPURE 302, Batch #52902 (CRL110302-2)
C	=	ENVIOPURE 303, Batch #E2034 (CRL110302-3)
D	=	ENVIOPURE 304, Batch #E2035 (CRL110302-4)
E	=	ENVIOPURE 305, Batch #7152 (CRL110302-5)
F	=	ENVIOPURE 306, Batch #7162 (CRL110302-6)
G	=	ENVIOPURE 307, Batch #7172 (CRL110302-7)
H	=	ENVIOPURE 308, Batch #7182 (CRL110302-8)
I	=	ENVIOPURE 309, Batch #7192 (CRL110302-9)
J	=	ENVIOPURE 310 (CRL110302-10)
K	=	White Petrolatum (CRL110302-11)
L	=	Vaseline (CRL110302-12)
M	=	Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
ocol Number: 3.03eu
e 53 of 60

**Table V
(Continued)
Summary Statistics for Multiple Treatment Comparisons for Between Treatments and
the Control**

1 Hour

Alpha	0.05
Error Degrees of Freedom	585
Error Mean Square	35.80002
Critical Value of Studentized Range	4.70451
Minimum Significant Difference	4.1503

Tukey Grouping*	Mean	N	Product
A	9.963	46	M
A	9.863	46	I
A	9.765	46	C
A	9.667	46	F
A	9.657	46	K
A	9.548	46	A
A	9.476	46	G
A	9.354	46	J
A	9.352	46	L
A	9.257	46	D
A	8.948	46	B
A	8.850	46	E
A	10.261	46	H
Means with the same letter are not significantly different.*			

Treatment Code

- A = ENVIOPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIOPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIOPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIOPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIOPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIOPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIOPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIOPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIOPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIOPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 54 of 60

**Table V
(Continued)
Summary Statistics for Multiple Treatment Comparisons for Between Treatments and
the Control**

6 Hours

Alpha	0.05
Error Degrees of Freedom	585
Error Mean Square	39.24021
Critical Value of Studentized Range	4.70451
Minimum Significant Difference	4.3451

Tukey Grouping*	Mean	N	Product
A	9.676	46	D
A	9.663	46	M
A	9.576	46	G
A	9.517	46	L
A	9.489	46	A
A	9.465	46	F
A	9.413	46	H
A	9.389	46	K
A	9.289	46	I
A	9.191	46	E
A	9.046	46	J
A	8.998	46	C
A	8.859	46	B

Means with the same letter are not significantly different.*

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 55 of 60

**Table V
(Continued)
Summary Statistics for Multiple Treatment Comparisons for Between Treatments and
the Control**

Differences from Baseline at 1 Hour

Alpha	0.05
Error Degrees of Freedom	585
Error Mean Square	0.119767
Critical Value of Studentized Range	4.70451
Minimum Significant Difference	0.2401

Tukey Grouping*	Mean	N	Product
A	0.00002	46	F
A	-0.00022	46	H
A	-0.00246	46	A
A	-0.00751	46	C
A	-0.01427	46	I
A	-0.01865	46	K
A	-0.03435	46	L
A	-0.04407	46	J
A	-0.04871	46	M
A	-0.07248	46	B
A	-0.07959	46	E
A	-0.08635	46	G
A	-0.09317	46	D
Means with the same letter are not significantly different.*			

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 56 of 60

**Table V
(Continued)
Summary Statistics for Multiple Treatment Comparisons for Between Treatments and
the Control**

Differences from Baseline at 6 Hours

Alpha	0.05
Error Degrees of Freedom	585
Error Mean Square	0.11039
Critical Value of Studentized Range	4.70451
Minimum Significant Difference	0.2305

Tukey Grouping*	Mean	N	Product
A	-0.12890	46	B
A	-0.11465	46	I
A	-0.10242	46	J
A	-0.10093	46	G
A	-0.08023	46	E
A	-0.07917	46	H
A	-0.07876	46	D
A	-0.07649	46	C
A	-0.07358	46	L
A	-0.06938	46	K
A	-0.06234	46	A
A	-0.05305	46	M
A	-0.03668	46	F
Means with the same letter are not significantly different.*			

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

Final Report
Sponsor: React, Inc.
Study Number: CRL110302
Protocol Number: 3.03eu
Page 57 of 60

Appendix I

Subject Demographics

Subject Number	Subject Initials	CRL ID #	Age	Sex
1	SF	16570	37	F
2	DB	04161	42	F
3	RN	14458	30	F
4	MR	14674	54	M
5	MK	11942	30	F
6	HP	16504	52	F
7	SR	15278	37	F
8	SM	07079	48	F
9	SA	16595	37	M
10	AA	16648	34	F
11	JP	01743	46	F
12	AA	07153	22	F
13	NR	02271	51	F
14	AM	15571	52	F
15	EK	05468	37	F
16	PH	17254	38	F
17	LD	14521	50	F
18	DS	16164	18	M
19	JH	16622	35	M
20	IK	17258	31	F
21	KH	16635	34	F
22	KL	16938	46	F
23	DD	16939	44	F
24	BP	16457	29	F
25	BB	08756	52	F
26	SS	16050	45	F
27	SC	14448	47	F
28	BB	17006	22	F

Subject Number	Subject Initials	CRL ID #	Age	Sex
29	DM	16596	39	F
30	HP	14493	38	F
31	NQ	10096	55	F
32	BS	16561	34	F
33	MH	15294	41	F
34	AA	17289	29	M
35	LR	10522	41	F
36	VS	04571	34	F
37	BR	15151	54	F
38	CM	08557	25	F
39	CS	15883	46	F
40	CD	13078	35	F
41	DR	11074	48	F
42	VD	10340	44	F
43	AH	07601	36	F
44	JK	10944	46	F
45	DD	16859	39	F
46	SS	14733	46	F
47	WJ	14108	47	F
48	XS	07816	47	M
49	VH	15824	54	F
50	JW	13956	42	M
51	LM	09589	41	F
52	CS	14200	38	F
53	CD	00003	47	F
54	LA	16749	45	F
55	IC	16936	23	F



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 58 of 60

Appendix II

Treatment Randomization

Subject Number	Treatment Designation for Each Site Number												
	1	2	3	4	5	6	7	8	9	10	11	12	13
1	E	J	B	L	D	G	I	M	H	C	A	F	K
2	F	K	C	M	E	H	J	A	I	D	B	G	L
3	G	L	D	A	F	I	K	B	J	E	C	H	M
4	H	M	E	B	G	J	L	C	K	F	D	I	A
5	I	A	F	C	H	K	M	D	L	G	E	J	B
6	J	B	G	D	I	L	A	E	M	H	F	K	C
7	K	C	H	E	J	M	B	F	A	I	G	L	D
8	L	D	I	F	K	A	C	G	B	J	H	M	E
9	M	E	J	G	L	B	D	H	C	K	I	A	F
10	A	F	K	H	M	C	E	I	D	L	J	B	G
11	B	G	L	I	A	D	F	J	E	M	K	C	H
12	C	H	M	J	B	E	G	K	F	A	L	D	I
13	D	I	A	K	C	F	H	L	G	B	M	E	J
14	E	J	B	L	D	G	I	M	H	C	A	F	K
15	F	K	C	M	E	H	J	A	I	D	B	G	L
16	G	L	D	A	F	I	K	B	J	E	C	H	M
17	H	M	E	B	G	J	L	C	K	F	D	I	A
18	I	A	F	C	H	K	M	D	L	G	E	J	B

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
ge 59 of 60

Appendix II (Continued) Treatment Randomization

Subject Number	Treatment Designation for Each Site Number												
	1	2	3	4	5	6	7	8	9	10	11	12	13
19	J	B	G	D	I	L	A	E	M	H	F	K	C
20	K	C	H	E	J	M	B	F	A	I	G	L	D
21	L	D	I	F	K	A	C	G	B	J	H	M	E
22	E	J	G	L	B	D	H	C	K	I	A	F	M
23	A	F	K	H	M	C	E	I	D	L	J	B	G
24	B	G	L	I	A	D	F	J	E	M	K	C	H
25	C	H	M	J	B	E	G	K	F	A	L	D	I
26	D	I	A	K	C	F	H	L	G	B	M	E	J
27	E	J	B	L	D	G	I	M	H	C	A	F	K
28	F	K	C	M	E	H	J	A	I	D	B	G	L
29	G	L	D	A	F	I	K	B	J	E	C	H	M
30	H	M	E	B	G	J	L	C	K	F	D	I	A
31	I	A	F	C	H	K	D	M	L	G	E	J	B
32	J	B	G	D	I	L	A	E	M	H	F	K	C
33	K	C	H	E	J	M	B	F	A	I	G	L	D
34	L	D	I	F	K	A	C	G	B	J	H	M	E
35	M	E	J	G	L	B	D	H	C	K	I	A	F
36	A	F	K	H	M	C	E	I	D	L	J	B	G

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control



Clinical Research Laboratories, Inc.

al Report
ent: React, Inc.
dy Number: CRL110302
tocol Number: 3.03eu
e 60 of 60

Appendix II (Continued) Treatment Randomization

Subject Number	Treatment Designation for Each Site Number												
	1	2	3	4	5	6	7	8	9	10	11	12	13
37	B	G	L	I	A	D	F	J	E	M	K	C	H
38	C	H	M	J	B	E	G	K	F	A	L	D	I
39	D	I	A	K	C	F	H	L	G	B	M	E	J
40	E	J	B	L	D	G	I	M	H	C	A	F	K
41	F	K	C	M	E	H	J	A	I	D	B	G	L
42	G	L	D	A	F	I	K	B	J	E	C	H	M
43	H	M	E	B	G	J	L	C	K	F	D	I	A
44	I	A	F	C	H	K	M	D	L	G	E	J	B
45	J	B	G	D	I	L	A	E	M	H	F	K	C
46	K	C	H	E	J	M	B	F	A	I	G	L	D
47	L	D	I	F	K	A	C	G	B	J	H	M	E
48	M	E	J	G	L	B	D	H	C	K	I	A	F
49	A	F	K	H	M	C	E	I	D	L	J	B	G
50	B	G	L	I	A	D	F	J	E	M	K	C	H
51	E	J	B	L	D	G	I	M	H	C	A	F	K
52	F	K	C	M	E	H	J	A	I	D	B	G	L
53	G	L	D	A	F	I	K	B	J	E	C	H	M
54	H	M	E	B	G	J	L	C	K	F	D	I	A
55	I	A	F	C	H	K	M	D	L	G	E	J	B

Treatment Code

- A = ENVIROPURE 301, Batch #H2031 (CRL110302-1)
- B = ENVIROPURE 302, Batch #52902 (CRL110302-2)
- C = ENVIROPURE 303, Batch #E2034 (CRL110302-3)
- D = ENVIROPURE 304, Batch #E2035 (CRL110302-4)
- E = ENVIROPURE 305, Batch #7152 (CRL110302-5)
- F = ENVIROPURE 306, Batch #7162 (CRL110302-6)
- G = ENVIROPURE 307, Batch #7172 (CRL110302-7)
- H = ENVIROPURE 308, Batch #7182 (CRL110302-8)
- I = ENVIROPURE 309, Batch #7192 (CRL110302-9)
- J = ENVIROPURE 310 (CRL110302-10)
- K = White Petrolatum (CRL110302-11)
- L = Vaseline (CRL110302-12)
- M = Untreated Control